Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment

Recruiting Phase 4 Interventional Study
Congenital Adrenal Hyperplasia
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
150 (estimated)
Sponsor
Federico II University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This is a controlled, open study designed to compare the effects of dual-release hydrocortisone preparations versus conventional glucocorticoid therapy on clinical, anthropometric parameters, metabolic syndrome, hormonal profile, bone status, quality of life, reproductive, sexual and psychological functions and treatment compliance in patients affected by congenital adrenal hyperplasia due to 21 O…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * males and females aged \>18 years; * established diagnosis of adrenal insufficiency in congenital adrenal hyperplasia due to 21-hydroxylase deficiency; * stably treated with conventional glucocorticoids, available to change their regimen according to random allocation * writte…
Contacts

Rosario Pivonello, M.D., PhD, Professor

+390817464983

rosario.pivonello@unina.it

CONTACT